Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia

Clin Interv Aging. 2016 Feb 17:11:153-7. doi: 10.2147/CIA.S100274. eCollection 2016.

Abstract

Objective: This study examined the risk factors for decreased bone mineral density (BMD) in postmenopausal women with schizophrenia.

Methods: Cluster sampling method was adopted in this large-sample, cross-sectional study. A total of 219 postmenopausal female inpatients with schizophrenia were selected and interviewed in Beijing. The average age of the patients was 60.4±7.0 years. Clinical assessment instruments included the Positive and Negative Syndrome Scale (PANSS) and a questionnaire with detailed general information and disease-related investigations. Laboratory measurements included prolactin (PRL), estradiol, progesterone, thyroid stimulating hormone, FT3, and FT4. BMD testing was performed by dual-energy X-ray absorptiometry.

Results: The prevalence of osteoporosis or osteopenia was 66.2% (n=145). Decreased BMD was associated with age, illness duration, therapeutic dose (equivalent chlorpromazine dose), treatment duration, PANSS-negative scores, body mass index (BMI), daily exercises (min/d), drinking (unit/wk), PRL, and estradiol. Multiple logistic regression analysis revealed that age, treatment duration, PANSS-negative score, BMI, and PRL were significantly associated with decreased BMD.

Conclusion: Prevalence of BMD loss was higher in Chinese postmenopausal women with schizophrenia compared to the normal BMD group. A combination of demographic and clinical factors play important roles in determining decreased BMD, including older age, longer treatment duration, more PANSS-negative scores, higher BMI, and higher PRL level.

Keywords: bone density; risk factors; schizophrenia.

MeSH terms

  • Absorptiometry, Photon
  • Aged
  • Beijing
  • Body Mass Index
  • Bone Density*
  • Cross-Sectional Studies
  • Estradiol / blood
  • Female
  • Humans
  • Logistic Models
  • Middle Aged
  • Osteoporosis / epidemiology*
  • Postmenopause*
  • Progesterone / blood
  • Prolactin / blood
  • Risk Factors
  • Schizophrenia / complications*
  • Thyrotropin / blood

Substances

  • Progesterone
  • Estradiol
  • Prolactin
  • Thyrotropin